Common pitfalls in preclinical cancer target validation
Nature Reviews Cancer 17, 425 (2017).
doi:10.1038/nrc.2017.32
Author: William G. Kaelin
An alarming number of papers from laboratories nominating new cancer drug targets contain findings that cannot be reproduced by others or are simply not robust enough to justify drug discovery efforts. This problem probably has many causes, including an underappreciation of the danger of being
Source: Nature Reviews Cancer - Category: Cancer & Oncology Authors: William G. Kaelin Tags: Perspectives Source Type: research
More News: Cancer | Cancer & Oncology